Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Michael Borodkin

Ophthalmology New York, NY Medical Doctor

NPI 1801903349 CMS profile 263121

178 E 71St St, New York, NY 10021

Open in the dashboard

General payments

$1,064

32 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Borodkin of New York, NY is reported in the CMS Open Payments database as having received $1,064 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $460 15
2024 General $101 4
2023 General $72 4
2022 General $121 4
2021 General $291 4
2020 General $19 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Borodkin
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Michael Borodkin were reported at $460. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Michael Borodkin Ophthalmology median Middle half National median
2019 $0 $258 $104–$655 $163
2020 $19 $126 $45–$321 $114
2021 $291 $205 $76–$534 $132
2022 $121 $266 $100–$678 $149
2023 $72 $308 $117–$745 $160
2024 $101 $340 $127–$846 $164
2025 $460 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Sun Pharmaceutical Industries Inc. $348 11 payments
  2. TissueTech, Inc. $313 9 payments
  3. Ocular Therapeutix, Inc. $125 1 payment
  4. Alcon Vision LLC $76 3 payments
  5. AbbVie, Inc. $73 3 payments
  6. Astellas Pharma US Inc $33 1 payment
  7. Amgen Inc. $27 1 payment
  8. Dompe US, Inc. $26 1 payment
  9. Horizon Therapeutics plc $24 1 payment
  10. Carl Zeiss Meditec AG $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $1,045 31 payments
  2. Gift $19 1 payment
Products named General payments · program years 2020–2025
  1. Cequa $348 11 payments
  2. DEXTENZA $125 1 payment
  3. Xelpros $75 4 payments
  4. TRYPTYR $56 2 payments
  5. LUMIGAN $38 2 payments
  6. PROKERA $35 1 payment
  7. AMNIOGRAFT $35 1 payment
  8. OZURDEX $35 1 payment
  9. Izervay $33 1 payment
  10. TEPEZZA $27 1 payment
  11. Other $89 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

336

Median for Ophthalmology: 891

Drug cost

$55,045

Median for Ophthalmology: $68,233

Branded share of claims

47%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 47 $29,850
Cequa Cyclosporine Brand 13 $9,726
Prolensa Bromfenac Sodium Brand 19 $6,417
Prednisolone Acetate Generic 49 $2,690
Tafluprost Tafluprost/Pf Brand 15 $2,065
Brimonidine Tartrate Generic 11 $1,543
Latanoprost Generic 70 $877
Moxifloxacin Moxifloxacin Hcl Brand 34 $608
Ofloxacin Generic 32 $384
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 12 $381

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$153,102

Medicare's payments for the services billed

Medicare patients

728

Average age 78

Services billed

1,846

479 women, 249 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 51%
Osteoporosis 28%
Ischemic heart disease 27%
Cancer 21%
Diabetes 18%
Depression 15%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Izervay
  • Astellas Pharma US Inc $33
$33 — —
TEPEZZA
  • Amgen Inc. $27
$27 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $17
$17 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record